Stock under Trader's Radar: Alcobra Ltd. Ord (ADHD)

Lloyd Doyle
October 13, 2017

At the end of 6/30/2017 reporting period, 7 institutional holders increased their position in Alcobra Ltd. (NASDAQ:ADHD) by some 339,767 shares, 21 decreased positions by 2,209,702 and 9 held positions by 6,289,453.

According to Zacks, "Alcobra a biopharmaceutical company". It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Alcobra headquartered in Tel Aviv, Israel.

ADHD has been the subject of a number of other reports.

WBB Securities "Upgrades" Alcobra Ltd. Ord (NASDAQ:ADHD) in a research note issued to investors on 10/09/17 to Speculative Buy with price target of $2. Company shares last traded at $1.15 barely above $1.06, the 50 day moving average and a tad higher than the 200 day moving average of $1.11. Hot Stocks Point (HSP) makes sure to keep the information up to date and correct, but we didn't suggest or recommend buying or selling of any financial instrument unless that information is subsequently confirmed on your own. Alcobra has a consensus rating of "Hold" and an average price target of $1.56.

Alcobra (NASDAQ:ADHD) opened at 1.095 on Monday.

In the last earnings report the EPS was $-0.76 and is projected to be $-0.77 for the current year with 27,562,000 shares now outstanding.

Additionally on 2/09/17 Roth Capital "Upgrades" Alcobra Ltd. Ord (NASDAQ:ADHD) to Buy setting price target at $0 and on 1/18/17 Jefferies "Downgrades" the stock to Hold at $1.3. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and worldwide copyright and trademark legislation.

These firms have modified their investment in ADHD.

Covering sell-side analysts have recently weighed in on shares of CorMedix, Inc.

According to analysts Alcobra Ltd. Ord (NASDAQ:ADHD)'s minimum EPS for the current quarter is at $-0.68 and can go high up to $-0.08. Citadel Advisors LLC now owns 100,114 shares of the biotechnology company's stock valued at $114,000 after buying an additional 101,514 shares during the period. Worth Venture Partners LLC grew its stake in shares of Alcobra by 35.6% during the 2nd quarter. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded 1.16%. Finally, Royce & Associates LP grew its stake in shares of Alcobra by 15.5% in the 1st quarter. Royce & Associates LP now owns 745,055 shares of the biotechnology company's stock valued at $849,000 after acquiring an additional 100,000 shares during the period.

Other reports by Iphone Fresh

Discuss This Article